Genome-Wide Meta-Analysis Identifies Variants in

Autor: Meta H M, Diekstra, Jesse J, Swen, Loes F M, van der Zanden, Sita H, Vermeulen, Epie, Boven, Ron H J, Mathijssen, Koya, Fukunaga, Taisei, Mushiroda, Fumiya, Hongo, Egbert, Oosterwijk, Anne, Cambon-Thomsen, Daniel, Castellano, Achim, Fritsch, Jesus Garcia, Donas, Cristina, Rodriguez-Antona, Rob, Ruijtenbeek, Marius T, Radu, Tim, Eisen, Kerstin, Junker, Max, Roessler, Ulrich, Jaehde, Tsuneharu, Miki, Stefan, Böhringer, Michiaki, Kubo, Lambertus A L M, Kiemeney, Henk-Jan, Guchelaar

Publikováno v: Cancers. 14(12)

Individual response to sunitinib in metastatic renal cell carcinoma (mRCC) patients is highly variable. Earlier, sunitinib outcome was related to single nucleotide polymorphisms (SNPs) in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fc84cc26542714b71bffbb189b1efeea
https://pubmed.ncbi.nlm.nih.gov/35740506

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer

Autor: B. Moritz, Meta H M Diekstra, Fritz Sörgel, Ulrich Jaehde, Henk-Jan Guchelaar, K. Mross, Danny Houtsma, Christoph Stelzer, Achim Fritsch, Thomas Gauler, Egbert Oosterwijk, Lambertus A. Kiemeney, D J A R Moes, L. Bergmann, F. Kanefendt, Max Roessler, Stephen L. Hauser, Jesse J. Swen, Martina Kinzig, D. Schindele

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology. 6:604-613

The tyrosine kinase inhibitor sunitinib is used as first-line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed-dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9ae513ba099b16deffb24ff1c83d70e2
https://doi.org/10.1002/psp4.12210

A genetic polymorphism in ctla-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma

Autor: Marius T. Radu, Hans Gelderblom, Karel K. M. Koudijs, Xiaoyan Liu, Egbert Oosterwijk, Daniel Castellano, Max Roessler, Kerstin Junker, Jesús García-Donas, Henk-Jan Guchelaar, Asgerdur Sverrisdottir, Ron H.J. Mathijssen, Jesse J. Swen, Stefan Böhringer, Lambertus A. Kiemeney, Cristina Rodríguez-Antona, Epie Boven, Sita H. Vermeulen, Anne Y. Warren, Meta H M Diekstra, Kristin Alexiusdottir, Valentin Ambert, Tim Eisen, Brian I. Rini

Publikováno v: Clinical Cancer Research, 24(10), 2350-2356. American Association for Cancer Research Inc.
Liu, X, Swen, J J, Diekstra, M H M, Boven, E, Castellano, D, Gelderblom, H, Mathijssen, R H J, Vermeulen, S H, Oosterwijk, E, Junker, K, Roessler, M, Alexiusdottir, K, Sverrisdottir, A, Radu, M T, Ambert, V, Eisen, T, Warren, A, Rodríguez-Antona, C, García-Donas, J, Bohringer, S, Koudijs, K K M, Kiemeney, L A L M, Rini, B I & Guchelaar, H-J 2018, ' A genetic polymorphism in ctla-4 is associated with overall survival in sunitinib-treated patients with clear cell metastatic renal cell carcinoma ', Clinical Cancer Research, vol. 24, no. 10, pp. 2350-2356 . https://doi.org/10.1158/1078-0432.CCR-17-2815
Clinical Cancer Research, 24, 2350-2356
Clinical Cancer Research, 24, 10, pp. 2350-2356
Clinical Cancer Research, 24(10), 2350-2356

Purpose: The survival of patients with clear cell metastatic renal cell carcinoma (cc-mRCC) has improved substantially since the introduction of tyrosine kinase inhibitors (TKI). With the fact that TKIs interact with immune responses, we investigated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2941878222dfd726531bf29dc154a5a
https://research.vumc.nl/en/publications/8055773b-ba55-4340-ba49-a72fceb1b89b

A Genetic Polymorphism in

Autor: Xiaoyan, Liu, Jesse J, Swen, Meta H M, Diekstra, Epie, Boven, Daniel, Castellano, Hans, Gelderblom, Ron H J, Mathijssen, Sita H, Vermeulen, Egbert, Oosterwijk, Kerstin, Junker, Max, Roessler, Kristin, Alexiusdottir, Asgerdur, Sverrisdottir, Marius T, Radu, Valentin, Ambert, Tim, Eisen, Anne, Warren, Cristina, Rodríguez-Antona, Jesus, García-Donas, Stefan, Böhringer, Karel K M, Koudijs, Lambertus A L M, Kiemeney, Brian I, Rini, Henk-Jan, Guchelaar

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 24(10)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::b6df1ea69e558a5015d97cf241a1b510
https://pubmed.ncbi.nlm.nih.gov/29490989

Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity

Autor: Henk-Jan Guchelaar, Max Roessler, Arna Oskarsdottir, Thorunn Rafnar, Meta H M Diekstra, Valentin Ambert, Rosa Guarch Troyas, Lambertus A. Kiemeney, Kerstin Junker, Anna Martinez-Cardus, J.C. Oosterwijk-Wakka, Gisli Masson, Jesus Garcia Donas, Anne Cambon-Thomsen, Lodewyk F. A. Wessels, Tim Eisen, Cristina Rodríguez-Antona, Achim Fritsch, Ulrich Jaehde, Marius T. Radu, Arndt Hartmann, Sita H. Vermeulen, Daniel Castellano, Anne Y. Warren, Kari Stefansson, Loes F.M. van der Zanden, Jake S.F. Maurits, Egbert Oosterwijk, Christina A. Hulsbergen-van de Kaa, Rob Ruijtenbeek

Publikováno v: Urologic Oncology-Seminars and Original Investigations, 35, 8, pp. 529.e9-529.e16
Urologic Oncology-Seminars and Original Investigations, 35, 529.e9-529.e16
Urologic oncology-seminars and Original Investigations, 35(8):ARTN 529.e9. Elsevier Science
Repisalud
Instituto de Salud Carlos III (ISCIII)
Urologic Oncology: Seminars and Original Investigations, 35(8)

OBJECTIVE: For patients with metastatic renal cell cancer (mRCC), treatment choice is mainly based on clinical parameters. With many treatments available and the limited response to treatment and associated toxicities, there is much interest in ident

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b27ac13d3e48403246a3373a7273b5a
https://hdl.handle.net/2066/177333